Browse drugs

… 10 mg monotherapy led to notable CBR rates and ALP reductions. Seladelpar monotherapy was well tolerated and had a similar safety profile…

…Seladelpar is a first-in-class delpar (selective PPAR-delta agonist) indic…

…brates/OCA (total, n = 131; 83%). At month 18, among continuous seladelpar patients, 9/15 (60%) patients with prior fibrate/OCA use achiev…

…Seladelpar is a first-in-class delpar (selective PPAR-delta agonist) indic…

…followed by the TB component (3M, −0.11; 1Y, −0.09; 2Y, −0.13). Seladelpar treatment for 3M, 1Y, and 2Y led to predicted changes in TFS wi…

…fness by baseline subgroups.Baseline was defined at the time of seladelpar initiation.n = the number of evaluable patients at each time po…

…n (B), ALP % change from BL (C) through 36 months of open-label seladelpar treatmentn/N = number of responders at each time point/total nu…

…% CI 23.7 – 50.3)) SELADELPAR (ARR = 40.9 (95% CI 28.1 – 53.8)) ELAFIBRANOR (ARR = 47.2 (95% CI 36.4 – 57.9)) ARR = 10.2 (-6.9 ; 27,3) p = …

…ry cholangitis (PBC) and significantly impairs quality of life. Seladelpar (SEL), a first-in-class delpar (selective PPAR-delta agonist), …

… was recently withdrawn from the US creating a therapeutic gap. Seladelpar (SEL), approved in 2024 in the US for patients with PBC and an …

…py, while 27% were prescribed second-line treatments, including Bezafibrate (31 patients), Obeticholic acid (20 patients), and Elafibranor …